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To the Editor:
Recently, a real-world study of primarily Medicare-insured patients compared the risk of recurrent venous thromboembolism (VTE) and major bleeding associated with rivaroxaban, warfarin, and low-molecular weight heparin (LMWH) following a first-episode of VTE among patients with cancer. 1 Results suggested that rivaroxaban treatment is associated with a lower risk of recurrent VTE versus LMWH or warfarin, and that the rate of major bleeding does not significantly differ across treatments. 1 As this original study was conducted among an elderly population (age ≥65 years), we sought to Baseline characteristics for the weighted cohorts were obtained by using inverse probability of treatment weights; weighted on the following variables: age, sex, cancer type, region, time from first cancer to initial VTE, time to anticoagulant initiation, year of first VTE, setting in which the VTE was diagnosed (inpatient, outpatient, or emergency room), type of VTE (DVT, PE, or both), treatment with an antineoplastic agent, insurance type, Charlson comorbidity index, health care costs, and health care resource used during the 6-month period before the first VTE.
b
For continuous variables, the standardized difference is calculated by dividing the absolute difference in means of the treated A and treated B cohorts by the pooled SD of both groups. The pooled SD is the square root of the average of the squared SDs. For categorical variables with two levels, the standardized difference is calculated using the following equation where P is the respective proportion of participants in each group: (P assess the risk of recurrent VTE and major bleeding associated with rivaroxaban, LMWH, and warfarin treatment following a first-episode of VTE in commercially-insured-and younger-patients.
We have previously detailed our methodology. 1 2 Study outcomes were assessed using Cox proportional hazards models with hazard ratios (HRs) and KaplanMeier rates. Inverse probability of treatment weights (IPTW) based on propensity scores were used to adjust for baseline confounding.
A total of 13 804 commercially-insured patients were included.
Of these, 3370 were initiated on rivaroxaban, 4774 on warfarin, and 4313 on LMWH. IPTW resulted in generally well-balanced cohorts (ie, standardized difference <10%). Mean ages among the rivaroxaban, warfarin, and LMWH cohorts were 62.6, 63.9, and 60.2 years, respectively, which is~10 years younger than patients in our previous study. 1 Similarly, patients had fewer comorbidities relative to those included in Streiff et al.'s study (Quan-Charlson comorbidity index 3.7 vs 4.7). Other baseline characteristics were generally similar between the two studies (see Table 1 ).
The mean (median) durations of treatment were 5.5 (3.6), 3.5 (2.0), and 5.8 (4.0) months for patients initiated on rivaroxaban, LMWH, and warfarin, respectively. Relative to patients initiated on LMWH, the rate of recurrent VTE was 17% lower for patients initiated on rivaroxaban (P = 0.010; Figure 1A ). Rates of recurrent VTE
were not significantly different between the rivaroxaban versus FIGURE 1 Cumulative incidence of recurrent VTE 1 with pairwise comparisons of all cohorts 2 warfarin cohorts (P = 0.456; Figure 1B ) and warfarin versus LMWH cohorts (P = 0.103; Figure 1C ). (LMWH: 11.0%; rivaroxaban: 4.0%). [3] [4] [5] It is likely that the similar findings noted in this study and previous clinical trials could be explained by age. More precisely, the mean age of the commercial population evaluated in our study was~62 years old, while the mean age of patients in the CATCH and CLOT trials were~59 and~62 years old, respectively; and the median age in the SELECT-D trial was 67 years old.
With respect to safety outcomes, the rate of major bleeding events at 6 months (LMWH:~5%; warfarin:~4%; rivaroxaban:~4%) are very similar to those reported in the CATCH (LMWH:~3%; warfarin:~3%), CLOT (LMWH: 6.0%; warfarin: 4.0%), and SELECT-D trials (LMWH: 4.0%; rivaroxaban: 6.0%). Despite these similarities, it is possible that the number of recurrent VTE was underestimated in the current study as the definition of recurrence was restricted to VTE documented during a hospitalization.
In this real-world analysis, patients with cancer who initiated standard-of-care LMWH had a 17% and 9% higher risk of recurrent VTE compared to rivaroxaban and warfarin, respectively, but a similar risk of major bleeding. These conclusions, which are based on a commercially-insured population, are similar to those of Streiff et al. 
